Skip to content

The safety and efficacy of G protein-biased µ -opioid receptor agonist oxeridine for patient-controlled intravenous analgesia after laparoscopic hepatectomy in patients: A prospective, non-interventional real-world study

The safety and efficacy of G protein-biased µ -opioid receptor agonist oxeridine for patient-controlled intravenous analgesia after laparoscopic hepatectomy in patients: A prospective, non-interventional real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106081
Enrollment
Unknown
Registered
2025-07-17
Start date
2025-07-24
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after laparoscopic hepatectomy

Interventions

Othelitin group:None

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.ASA grades I-III; 2.Age: 30-70 years old; 3.Patients undergoing laparoscopic hepatectomy under elective general anesthesia;

Exclusion criteria

Exclusion criteria: 1.Known cardiopulmonary diseases (untreated congenital heart disease, primary or secondary pulmonary hypertension, tumors, structural lung diseases); 2.Neuromuscular diseases; 3.Morbturally obese individuals (body mass index (BMI)) 35 kg/m ²; 4.Concurrent mental and neurological diseases, infections, severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, hematopoietic system diseases, etc; 5.Previous history of major abdominal surgery; 6.People with chronic pain, neuropathic pain, and those who have been using painkillers or other psychotropic drugs for a long time; 7.Those who are unwilling to be enrolled and unable to complete the trial plan;

Design outcomes

Primary

MeasureTime frame
NRS pain score;The number of cases with a postoperative NRS pain score >4 and the total incidence rate;

Secondary

MeasureTime frame
NRS pain score;The incidence of perioperative adverse respiratory events and non-respiratory adverse events;Postoperative rescue analgesic drugs, dosages and numbers;Depression score (SDS scale);Length of hospital stay;The intensity score of PONV greater than 5 points and the incidence of severe PONV (referring to the occurrence of nausea, gastric content ejection, or both twice or more at intervals of at least 6 ho;Time to leave the PACU after removal of the tracheal tube;Postoperative nausea and vomiting score (PONV score);Postoperative delirium agitation score (PAED score);Time of anal gas release, time of defecation;The calming effect upon entering the room (Funk score);Differences in TNF-a, IL-6, IL-1, GAS, MTI, and Ach;The number of patients requiring pain medication and the corresponding time points;extubation time;Fifteen recovery quality scores;Difference in pain NRS scores;Postoperative time to get out of bed;Pittsburgh Sleep Quality Index (PSQI scale);The differences in I-FEED scores and the incidence of POGD;

Countries

China

Contacts

Public ContactHe Liu

Huzhou Center Hospital

lh121061@163.com+86 572 2555285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026